First-in-Human Study of KO-947 in Non-Hematological Malignancies
Status:
Terminated
Trial end date:
2020-06-02
Target enrollment:
Participant gender:
Summary
This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated
dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed
and/or refractory, non-hematological malignancies. If an MTD cannot be identified, a
recommended phase 2 dose (RP2D) will be determined. In addition, two tumor specific extension
cohorts may be conducted to further characterize the safety and tolerability of KO-947 and
provide preliminary evidence of anti-tumor activity.